via Georgia State University
An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body’s immune response to influenza virus infection and offers broad protection against different viral strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
Recurring seasonal flu epidemics and potential pandemics are among the most severe threats to public health. Current seasonal influenza vaccines induce strain-specific immunity and are less effective against mismatched strains. Broadly protective influenza vaccines are urgently needed.
Intranasal vaccines are a promising strategy for combatting infectious respiratory diseases, such as influenza. They are more effective than vaccines injected into a muscle because they can induce mucosal immune responses in respiratory tracts, preventing infection at the portal of virus entry. They can also stimulate systemic immune responses throughout the body.
Scientists can overcome vaccine safety concerns and the long production phase of virus-based influenza vaccines by constructing intranasal vaccines with recombinant proteins or peptides. However, these vaccines are poor at producing immune responses, so it’s necessary to have potent mucosal adjuvants, substances that enhance the body’s immune response to antigens (the molecular structures on pathogens). The absence of appropriate mucosal adjuvants currently hinders the development of such a vaccine.
In this study, the researchers developed an intranasal influenza vaccine using recombinant hemagglutinin (HA), a protein found on the surface of influenza viruses, as the antigen component of the vaccine. HA is integral to the ability of influenza virus to cause infection.
They also created a two-dimensional nanomaterial (polyethyleneimine-functionalized graphene oxide nanoparticles) and found that it displayed potent adjuvant (immunoenhancing) effects on influenza vaccines delivered intranasally. The findings are published in the journal Proceedings of the National Academy of Sciences.
“Conventional flu vaccines predominantly induce antibody responses,” said Dr. Baozhong Wang, senior author of the study, principal investigator of the National Institutes of Health grant supporting the study and a professor in the Institute for Biomedical Sciences. “However, recent research demonstrates that lung resident memory T cell responses are indispensable for optimal cross-protection against pulmonary influenza infection. The development of lung resident T cell responses requires vaccination by a respiratory route or influenza virus infection. Our research opens a new path for the development of needle-free and logistically simplified intranasal flu vaccines for cross-protection.”
“In our study, we reported for the first time that two-dimensional graphene oxide nanomaterials had a potent adjuvant effect in boosting the immune responses of intranasal hemagglutinin (HA) vaccines,” said Dr. Chunhong Dong, lead author of the study and a postdoctoral research Fellow in Dr. Baozhong Wang’s lab in the Institute for Biomedical Sciences.
“This study gives new insights into developing high performance intranasal vaccine systems with two-dimensional sheet-like nanoparticles,” Dong said. “The graphene oxide nanoparticles have extraordinary attributes for drug delivery or vaccine development, such as the ultra-large surface area for high-density antigen loading, and the vaccine showed superior immunoenhancing properties in vitro and in vivo. The nanoplatform could be easily adapted for constructing mucosal vaccines for different respiratory pathogens.”
The study, conducted in mice and cell culture, found the nanoparticles significantly enhanced immune responses at mucosal surfaces and throughout the body in mice. The robust immune responses conferred immune protection against influenza virus challenges by homologous (same) virus strains and heterologous (different) virus strains.
The results are also promising because needle-free, intranasal influenza vaccines possess superior logistical advantages over traditional injectable vaccines, such as easy administration with high acceptance for recipients and the avoidance of biohazardous waste.
Original Article: Intranasal Influenza Vaccine Enhances Immune Response and Offers Broad Protection, Biomedical Sciences Researchers Find
More from: Georgia State University | Emory University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Intranasal nanoparticle influenza vaccine
- New strategy could lead to universal, long-lasting flu shot
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
- New influenza vaccine strategies aim to enhance protection with T-cell responses
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- Influenza Vaccination in Immunocompromised Patients
Yearly administration of the influenza vaccine is the main strategy to prevent influenza in immunocompromised patients. Here, we reviewed the recent literature regarding the clinical significance ...
- Influenza News
Feb. 29, 2024 — U.S. flu vaccines are likely to move from quadrivalent to trivalent due to a change in circulating influenza viruses, according to a new ... Feb. 19, 2024 — The prospect of the ...
- Vaccine Developers Leverage mRNA and Other Powerful Technologies
Years from now, when we look back on today’s vaccine ... influenza. Osivax spun off from Axio, another French firm. Axio developed OligoDOM, the VLP technology that Osivax uses to make its vaccines.
Go deeper with Google Headlines on:
Intranasal nanoparticle influenza vaccine
[google_news title=”” keyword=”intranasal nanoparticle influenza vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Intranasal nanoparticle vaccines
- New vaccine effective against coronaviruses that haven't even emerged yet
Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with potential for future disease outbreaks -- including ...
- New mRNA vaccine for deadly brain cancer triggers a strong immune response
In clinical trials, the vaccine material is often packaged into tiny lipid nanoparticles, but the trials typically only deliver a small number of particles and the vaccines themselves take months, if ...
- Breakthrough Nanoparticle Targets Breast Cancer and Brain Tumors
In a recent study published in Proceedings of the National Academy of Sciences, scientists at the University of Miami Miller School of Medicine's Sylvester Comprehensive Cancer Center developed a ...
- Nanoparticle researchers develop microfluidic platform for better delivery of gene therapy for lung disease
Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.
- New strategy could lead to universal, long-lasting flu shot
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
Go deeper with Google Headlines on:
Intranasal nanoparticle vaccines
[google_news title=”” keyword=”intranasal nanoparticle vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]